Immunome

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on the bottom line, with a net loss of $73.1M compared to the expected $60.3M. The GAAP EPS of -$0.65 was also below the -$0.52 mean estimate, driven by higher-than-expected R&D spending as clinical trials for IM-1617 and IM-3050 commenced. However, the company maintained a strong cash position of $520M, extending its runway into 2028, and achieved a critical regulatory milestone with the FDA acceptance of the Varegacestat NDA.